Acclaimed actor Rupert Everett supports GAFFI to raise awareness of the scale of the challenge across the world
Neglected by policy makers and most international health agencies, today sees the launch of Global Action Fund for Fungal Infections (GAFFI), an international organisation set to highlight the plight of 300 million people worldwide and begin to reverse unnecessary death and suffering.
Fungal infections kill at least 1,350,000 patients with or following AIDS, cancer, TB and asthma as well as causing untold misery and blindness to tens of millions more worldwide. Yet its symptoms are mostly hidden and occur as a consequence of other health problems, and the tragedy is that many of the best drugs have been available for almost 50 years.
Today in the House of Commons, in London* – and simultaneously in New York – GAFFI will be officially launched by Hollywood star Rupert Everett and founding President, Professor David Denning of the University of Manchester, who will spell out the global issues and potential for great health improvements including local access to diagnostics, antifungal medicines and better medical training.
Rupert Everett at GAFFI launch
Blindness caused by fungal infection of the eye affects over 1 million adults and children globally because the tools are not available for rapid diagnosis and treatment. Skin fungal infections affect a billion people worldwide. Severe asthma with fungal allergy contributes to half of the 350,000 deaths from asthma each year, yet it is treatable with antifungal drugs. With tuberculosis about 20 per cent of patients develop lung fungal infection, which progresses to death over several years, unless arrested with treatment affecting an estimated burden of 1.2 million people worldwide. Fungal meningitis and pneumonia kills in excess of 1 million patients with AIDS every year, including many children, before treatment for HIV can even begin to work.
Professor Denning explains: “This is a global plague on an unappreciated scale. Whilst the World Health Organisation has just developed clinical guidelines for doctors for fungal meningitis in AIDS, other critical fungal infections are ignored. The lack of basic fungal diagnostic capability and unavailable treatments in many countries results in millions of avoidable deaths and illness. GAFFI is here to change this dismal situation.”
Rupert Everett has pledged to help GAFFI raise awareness among health professionals and the public. He says: “ I understand from the experts, that fungal diseases tend to be complicated requiring specialised diagnostic skills. Only when it is too late is the diagnosis possible on clinical grounds, but even then many conditions overlap. The tragedy is that many of the best drugs have been available in some countries for 40-50 years, but not where they are now most needed.”
But experts believe the tide could be turning: The launch of GAFFI comes hard on the heels of a statement from the World Medical Association’s annual meeting in Brazil last month urging national governments to ensure that diagnostic tests and fungal therapies are available for their populations.
GAFFI has a stellar international Board and Advisor group from the UK, USA, Brazil, India, Australia, Spain, Switzerland, Norway and Japan to guide the foundation’s work as it begins its many tasks to rescue patients. www.GAFFI.org.
For more information please contact Susan Osborne, Director of Communications, the Goodwork Organisation on 07836 229208 or email email@example.com
*Please Note: admission is by invitation only. Images of fungal infections, and interviews with speakers and patients, are available on request.
Notes to Editors
GAFFI is a registered International Foundation based in Geneva, focused on four major tasks related to serious fungal infections. These are:
- Universal access to fungal disease diagnostics for serious fungal disease
- Universal access to generic antifungal agents
- Better data on the number and severity of fungal infections
- Health professional education related to better recognition and care for patients with serious fungal disease.
David W. Denning FRCP FRCPath FMedSci
Professor of Infectious Diseases in Global Health, University of Manchester; Director, National Aspergillosis Centre, University Hospital of South Manchester, UK
David Denning is an infectious diseases clinician with expertise in fungal diseases. He manages the National Aspergillosis Centre, Manchester, the referral centre in the UK for all patients with chronic pulmonary aspergillosis. He and his talented team undertake basic research (genomics, pathogenesis and mechanisms of antifungal drug resistance), applied laboratory work (molecular and serological diagnostics), and clinical studies (description of the natural history of fungal infection, human genetics of aspergillosis and therapy studies). His current focus of interest is chronic and allergic pulmonary fungal disease, the global burden of fungal infection and azole resistance in Aspergillus. He has published more than 400 papers, books and book chapters, including an undergraduate textbook of Medicine. He is managing Editor of The Aspergillus Website at www.aspergillus.org.uk.
For information about fungal infections see www.LIFE-Worldwide.org